Tune Therapeutics
Dr. Charles A. Gersbach is the Acting Chief Scientific Officer and Co-Founder of Tune Therapeutics.
A renowned academic and genome engineer, Charlie is the John W. Strohbehn Distinguished Professor of Biomedical Engineering at Duke University, and Director of the Duke Center for Advanced Genomic Technologies.
His research is focused on genome and epigenome editing, cellular engineering, gene therapy, synthetic biology, and regenerative medicine. His work has led to entirely new approaches to programming cell biology and the treatment of genetic disease and has earned him numerous awards, along with induction as a Fellow of the American Institute for Medical and Biological Engineering. He is also the co-founder of three biotechnology companies and an advisor to several others.
He received his Ph.D. in Biomedical Engineering from the Georgia Institute of Technology and Emory University and completed postdoctoral training at The Scripps Research Institute.